NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 02:20PM ET
1.51
Dollar change
-0.06
Percentage change
-3.82
%
Index- P/E- EPS (ttm)-0.11 Insider Own43.37% Shs Outstand111.46M Perf Week-15.17%
Market Cap168.30M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float63.12M Perf Month6.34%
Enterprise Value164.69M PEG- EPS next Q- Inst Own2.70% Short Float0.95% Perf Quarter36.04%
Income-11.86M P/S- EPS this Y- Inst Trans210.00% Short Ratio1.70 Perf Half Y101.60%
Sales0.00M P/B42.76 EPS next Y- ROA-101.10% Short Interest0.60M Perf YTD116.89%
Book/sh0.04 P/C45.24 EPS next 5Y- ROE-250.49% 52W High1.91 -20.94% Perf Year70.51%
Cash/sh0.03 P/FCF- EPS past 3/5Y22.52% -10.24% ROIC-301.40% 52W Low0.63 139.87% Perf 3Y95.93%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.72% 6.87% Perf 5Y-36.34%
Dividend TTM- EV/Sales- EPS Y/Y TTM35.57% Oper. Margin- ATR (14)0.11 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.02 Sales Y/Y TTM- Profit Margin- RSI (14)48.99 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.02 EPS Q/Q25.23% SMA20-2.27% Beta-0.61 Target Price3.00
Payout- Debt/Eq0.03 Sales Q/Q- SMA502.89% Rel Volume0.65 Prev Close1.57
Employees9 LT Debt/Eq0.00 Earnings- SMA20039.72% Avg Volume350.11K Price1.51
IPONov 20, 2018 Option/ShortYes / Yes EPS/Sales Surpr.- - Trades Volume171,111 Change-3.82%
Date Action Analyst Rating Change Price Target Change
Dec-22-20Initiated B. Riley Securities Buy $8
Dec-17-18Initiated Laidlaw Buy
Jun-13-25 10:30AM
08:30AM
May-23-25 07:00AM
May-15-25 08:00AM
May-12-25 07:00AM
07:00AM Loading…
May-09-25 07:00AM
May-06-25 07:00AM
Apr-30-25 05:39AM
Apr-24-25 11:14AM
Apr-23-25 07:00AM
Apr-02-25 08:00AM
Mar-26-25 07:58AM
Mar-25-25 08:00AM
Mar-17-25 08:00AM
Mar-14-25 08:30AM
08:00AM Loading…
Mar-04-25 08:00AM
Mar-02-25 09:25AM
Feb-27-25 08:00AM
Feb-25-25 08:00AM
Feb-21-25 08:00AM
Feb-18-25 08:00AM
Feb-11-25 09:15AM
Jan-23-25 03:00PM
08:54AM
Jan-22-25 04:05PM
Jan-10-25 08:00AM
Jan-08-25 07:00AM
Dec-17-24 07:00AM
Dec-05-24 07:07AM
Dec-04-24 07:00AM
07:28AM Loading…
Nov-20-24 07:28AM
Nov-19-24 07:00AM
Nov-01-24 01:00PM
Oct-30-24 10:29PM
08:30AM
Oct-26-24 05:49PM
Oct-19-24 05:27PM
Sep-19-24 07:00AM
Aug-19-24 07:00AM
Aug-14-24 07:00AM
Aug-10-24 02:00PM
Jul-24-24 07:00AM
Jun-28-24 11:01AM
07:53AM
Jun-26-24 07:00AM
Jun-11-24 08:45AM
08:00AM
Jun-06-24 09:00AM
Jun-04-24 09:00AM
May-30-24 07:00AM
May-13-24 07:00AM
Apr-25-24 10:00AM
Apr-23-24 09:32AM
07:00AM
Apr-22-24 07:00AM
Apr-19-24 07:00AM
Apr-18-24 07:00AM
Apr-11-24 07:00AM
Mar-05-24 07:00AM
Jan-08-24 07:00AM
Jan-05-24 09:30AM
07:00AM
Dec-19-23 07:00AM
Dec-04-23 07:09AM
Nov-30-23 07:00AM
Nov-01-23 07:00AM
Oct-20-23 05:20AM
Oct-18-23 07:00AM
Oct-17-23 03:27AM
Oct-16-23 07:00AM
Oct-13-23 07:00AM
Oct-11-23 07:00AM
Sep-26-23 07:00AM
Sep-12-23 08:19AM
Sep-08-23 07:00AM
Sep-06-23 07:00AM
Aug-28-23 07:12AM
Aug-23-23 10:30AM
07:00AM
Aug-17-23 07:00AM
Aug-15-23 09:28AM
07:00AM
Aug-01-23 08:00AM
Jul-21-23 04:15PM
Jun-20-23 06:07AM
Jun-18-23 09:02AM
Jun-13-23 07:00AM
Jun-05-23 10:00AM
May-25-23 07:00AM
May-23-23 07:00AM
May-17-23 07:00AM
May-05-23 10:49AM
May-02-23 05:52AM
Apr-27-23 07:00AM
Apr-26-23 02:47PM
Apr-24-23 07:00AM
Apr-21-23 10:47AM
Apr-20-23 07:00AM
Apr-19-23 10:30AM
Apr-18-23 07:00AM
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer's. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.